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The therapeutic possibilities for LHRH analogues in the treatment of breast cancer were quickly apparent. Experimentally they cause regression of oestrogen dependent DMBA-induced rat mammary tumours (Nicolson & Maynard, 1979) . In the clinic, the analogues goserelin (Zoladex, ICI), buserelin and leuprorelin have all been shown to suppress plasma oestrogens within 2-3 weeks of starting treatment and to achieve clinical regression of metastatic breast cancer in premenopausal women (Klijn, 1984; Harvey et al., 1985; Williams et al., 1986 (Miller et al., 1985) , and low affinity LHRH binding sites have been shown both in this cell line and in 20 out of 30 fresh breast cancer specimens (Eidne et al., 1985) . Some clinical studies have reported occasional objective responses in postmenopausal women (Plowman et al., 1986; Harris et al., 1989) , but other groups including ourselves have found no significant clinical activity (Waxman et al., 1985; Crighton et al., 1989 (Buchanan et al., 1986; Ingle et al., 1986) . Indeed, the failure of tamoxifen to achieve postmenopausal oestrogen levels is probably a positive benefit rather than a disadvantage; unlike oophorectomy (and presumably LHR analogues) it does not appear to cause bone demineralisation, and it significantly lowers serum cholesterol and low density lipoproteins (Powles et al., 1990) .
The real test for the LHRH analogues is no longer against oophorectomy, but against tamoxifen. Are they more effective? Are they in any way better tolerated? How do their long term effects on bone demineralisation and plasma lipids compare? As with so many other new forms of breast cancer treatment, tamoxifen is still the one to beat.
